ALT — Altimmune, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326190 ·
Last close
$1.53
Market Cap
$297.72M
52W High
$6.44
52W Low
$1.50
ADV30
3,905,174
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -35,705,000 | -31,608,000 | 495,646,000 | 28,888,000 | 52,080,000 |
| Jun 2026 | 0 | — | -26,229,000 | -22,825,000 | 527,212,000 | 63,008,000 | 53,004,000 |
| Mar 2026 | 0 | — | -24,244,000 | -22,563,000 | 335,630,000 | 97,601,000 | 51,643,000 |
| Dec 2025 | 26,000 | — | -28,893,000 | -27,358,000 | 279,929,000 | 43,760,000 | 55,037,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-76,508,000
Investing CF
$-453,612,000
Financing CF
$410,023,000
CapEx
$-54,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.78
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-694,871,000
Inventory
—
Receivables
$3,341,000
ST Investments
$263,273,000
EBIT TTM
$-88,224,000
Pretax Income TTM
$-91,760,000
Interest Exp TTM
$3,536,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$26,000
EBITDA
$-113,496,000
Free Cash Flow
$-65,109,124
Enterprise Value
$91,242,648
Total Cash
$265,059,008
Total Debt
$36,202,000
Shares Out
194,589,451
Trailing EPS
$-0.71
Book Value
$2.28
ROE
-33.2%
ROA
-19.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,000 | -94,489,000 | -88,093,000 | 279,929,000 | 55,037,000 | 224,892,000 | -67,535,000 |
| Dec 2024 | 20,000 | -103,172,000 | -95,059,000 | 139,306,000 | 15,798,000 | 123,508,000 | -79,848,000 |
| Dec 2023 | 426,000 | -83,510,000 | -88,447,000 | 210,640,000 | 16,541,000 | 194,099,000 | -75,810,000 |
| Dec 2022 | -68,000 | -87,740,000 | -84,713,000 | 206,928,000 | 21,635,000 | 185,293,000 | -62,586,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$7,458,000
NetIncome TTM
$-91,760,000
OpCashFlow TTM
—
Assets (Latest)
$527,212,000
Forward EPS
$-0.70
Max Pain — expiry 2027-01-15
max pain strike: $2.00 · spot: $1.39 · call oi: 16,427 · put oi: 1,035
Expected Move to 2027-01-15:
±$0.80
(57.55%) —
implied range
$0.59 –
$2.19
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GALT | GALECTIN THERAPEUTICS INC | $293.47M | $2.91 | — |
| INO | INOVIO PHARMACEUTICALS, INC. | $305.31M | $1.63 | — |
| EVMN | Evommune, Inc. | $290.28M | $7.02 | — |
| EBS | Emergent BioSolutions Inc. | $288.44M | $5.61 | — |
| MPLT | MapLight Therapeutics, Inc. | $286.78M | $6.57 | — |
News headlines (Yahoo Finance, 1h cache)
Altimmune, Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:03 · Yahoo
Altimmune (ALT) Q3 2026 Earnings Call Transcript
2026-11-12 18:00 · Yahoo
What Altimmune (ALT) Said on Its Q3 Earnings Call
2026-11-12 16:15 · Yahoo
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
2026-11-12 12:30 · Yahoo
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
2026-11-12 12:15 · Yahoo
Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial
2026-11-09 20:00 · Yahoo
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
2026-11-05 15:00 · Yahoo
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
2026-11-05 13:00 · Yahoo
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
2026-10-27 12:00 · Yahoo
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
2026-10-19 12:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-13 16:25:52 | 2026-11-13 | Durso Jerome Benedict | Pres, CEO | P - Purchase | 1.62 | 30700 | 49694 |